Robert Page

PharmD
University of Colorado, Denver
Robert Page

Brief Bio

Robert Lee Page II, PharmD, MSPH is a Professor in the Departments of Clinical Pharmacy and Physical/Rehabilitative Medicine at the University of Colorado Denver, Schools of Pharmacy and Medicine (Aurora), and the clinical pharmacy specialist for the Division of Cardiology Section of Advanced Heart Failure and Heart Transplantation. He is also the Clinical Lead for the Colorado Evidenced Based Drug Utilization Program.

Dr. Page received his bachelors of science degree in biology and chemistry from Furman University (Greenville, SC); bachelors of science in pharmacy and Pharm.D. degrees from the Medical University of South Carolina (MUSC; Charleston); Masters of Science in Public Health with an epidemiology focus from the University of Colorado School of Medicine (Denver); and specialty residency in pharmacotherapy with a focus in cardiology from MUSC. He is a board-certified pharmacotherapy specialist with added qualifications in cardiology, a Board Certified Geriatric Pharmacist, and a Fellow of the following organizations: the Heart Failure Society of America, the American College of Clinical Pharmacy, the American Heart association (Council on Clinical Cardiology), the American Society of Consultant Pharmacists, and the American Society of Health-System Pharmacists. Dr Page has served on numerous AHA, HFSA, and ACC committees and is past chair of the Clinical Pharmacology Subcommittee of the Council on Clinical Cardiology, and has been an external reviewer for several ACCF/AHA cardiovascular management guidelines. Dr. Page has 25 years of clinical expertise in the management of patients with heart failure in both the outpatient and inpatient setting. He has published over 200 peer reviewed manuscripts, abstracts, and book chapters in the management of patients with cardiovascular disease.

Alliance Presentations

Medical Marijuana

Medical Marijuana and CBD Oil Use Pre and Post-Transplant

Thursday, September 24, 2020, at 3:00pm

Use of marijuana and the varied forms of cannabis is steadily on the rise in the US as more states move to legalize the substance for both medicinal and recreational purposes. Transplant programs across the country also have a varied approach regarding pre and post-transplant use, as clear guidelines are lacking. Research into the effects of THC has been limited by its illegality at the federal level. Drug interactions warrant further evaluation and study. This review offers insight into the pre and post-transplant approach to marijuana and CBD oil use, drug interactions, and a review of proposed potential guidelines.

Lifelong Networks

Our partners are the heart and soul of our organization. For more than 15 years, they have played a vital role providing quality education and programs to advance a shared mission.